Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24.32 | 21.75 | 17.72 | 17.93 | 20.79 | 20.52 | 23.32 | 25.51 | 23.45 | 16.57 | 20.21 | 22.96 |
| Expenses | 25.42 | 25.12 | 27.25 | 19.85 | 24.20 | 22.02 | 24.58 | 22.38 | 20.93 | 15.84 | 19.53 | 24.30 |
| Operating Profit | -1.10 | -3.37 | -9.53 | -1.92 | -3.41 | -1.50 | -1.26 | 3.13 | 2.52 | 0.73 | 0.68 | -1.34 |
| OPM % | -4.52% | -15.49% | -53.78% | -10.71% | -16.40% | -7.31% | -5.40% | 12.27% | 10.75% | 4.41% | 3.36% | -5.84% |
| Other Income | 0.09 | 0.16 | 0.65 | 0.07 | 0.20 | 0.03 | 0.62 | 7.15 | 6.13 | 5.32 | 1.35 | 0.18 |
| Interest | 0.19 | 0.21 | 0.27 | 0.16 | 0.32 | 0.28 | 0.26 | 0.30 | 0.28 | 0.16 | 0.09 | 0.21 |
| Depreciation | 0.44 | 0.43 | 0.46 | 0.40 | 0.43 | 0.38 | 0.39 | 0.39 | 0.39 | 0.39 | 0.41 | 0.42 |
| Profit before tax | -1.64 | -3.85 | -9.61 | -2.41 | -3.96 | -2.13 | -1.29 | 9.59 | 7.98 | 5.50 | 1.53 | -1.79 |
| Tax % | 0.00% | 0.78% | 0.00% | 0.00% | 0.00% | 0.00% | 13.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -1.64 | -3.88 | -9.61 | -2.41 | -3.96 | -2.13 | -1.46 | 9.58 | 7.98 | 5.50 | 1.52 | -1.79 |
| EPS in Rs | -0.62 | -1.48 | -3.66 | -0.92 | -1.51 | -0.81 | -0.50 | 3.25 | 2.71 | 1.87 | 0.52 | -0.61 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 77 | 91 | 63 | 79 | 83 | 86 | 83 |
| Expenses | 77 | 105 | 93 | 97 | 91 | 79 | 81 |
| Operating Profit | 1 | -14 | -30 | -18 | -8 | 7 | 3 |
| OPM % | 0.7% | -16% | -47% | -22% | -10% | 8% | 3.1% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 20 | 13 |
| Interest | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 7 | 7 | 7 | 2 | 2 | 2 | 2 |
| Profit before tax | -9 | -24 | -38 | -20 | -10 | 25 | 13 |
| Tax % | 115% | -19% | -19% | 0% | 2% | 0% | |
| Net Profit | -19 | -19 | -31 | -20 | -10 | 25 | 13 |
| EPS in Rs | -7.40 | -4.31 | -7.97 | -7.46 | -3.38 | 8.34 | 4.49 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 2% | 11% | -8% | ||
| Compounded Profit Growth | % | 27% | 47% | 551% | ||
| Stock Price CAGR | -5% | -16% | -15% | -58% | ||
| Return on Equity | % | -9% | -2% | 22% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 25 | 25 | 25 | 26 | 29 | 29 |
| Reserves | 54 | 63 | 49 | 39 | 69 | 93 |
| Borrowings | 31 | 25 | 7 | 6 | 8 | 9 |
| Other Liabilities | 52 | 83 | 29 | 19 | 18 | 17 |
| Total Liabilities | 162 | 196 | 110 | 90 | 124 | 148 |
| Fixed Assets | 108 | 110 | 15 | 14 | 14 | 15 |
| CWIP | 1 | 15 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 64 | 43 | 74 | 92 |
| Other Assets | 54 | 71 | 31 | 34 | 36 | 40 |
| Total Assets | 162 | 196 | 110 | 90 | 124 | 148 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 4 | -37 | -14 | -10 | 3 | 9 |
| Cash from Investing Activity | -5 | -25 | 0 | 0 | -45 | -3 |
| Cash from Financing Activity | 1 | 64 | 11 | 10 | 42 | 0 |
| Net Cash Flow | 0 | 2 | -3 | 0 | -0 | 7 |
| Free Cash Flow | -1 | -62 | -15 | -10 | 2 | 6 |
| CFO/OP | 1,519% | 261% | 48% | 56% | -26% | 131% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 65 | 71 | 74 | 75 | 88 | 69 |
| Inventory Days | 178 | 157 | 80 | 60 | 61 | 77 |
| Days Payable | 233 | 159 | 165 | 97 | 90 | 80 |
| Cash Conversion Cycle | 9 | 68 | -12 | 38 | 59 | 66 |
| Working Capital Days | -85 | 34 | -37 | 34 | 43 | 34 |
| ROCE % | -16% | -30% | -25% | -10% | 21% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 63.59% | 63.59% | 63.59% | 63.59% | 63.59% | 59.06% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.02% | 0.01% | 0.05% | 0.00% | 0.01% | 0.09% | 0.17% | 0.00% |
| DIIs | 2.46% | 3.86% | 3.86% | 3.86% | 3.86% | 3.86% | 10.38% | 10.38% | 10.38% | 10.38% | 10.38% | 10.38% |
| Public | 33.94% | 32.56% | 32.55% | 32.55% | 32.53% | 37.08% | 36.95% | 37.00% | 37.00% | 36.91% | 36.84% | 37.00% |
| No. of Shareholders | 10,686 | 10,028 | 11,432 | 11,543 | 11,282 | 10,521 | 10,537 | 10,317 | 10,078 | 10,532 | 10,741 | 11,161 |
Fundamentals
Market Cap₹ 166 Cr.
Current Price₹ 56.5
Stock P/E12.6
Book Value₹ 41.6
ROCE21.2 %
ROE22.0 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-8%
Compounded Profit Growth (TTM)551%
Consolidated figures.
Valuation
Market capRs 135 Cr
Enterprise valueRs 157 Cr
P/E (TTM)10.25x
Price to book1.55x
Price to sales1.63x
EV / EBITDA10.07x
EV / EBIT11.23x
EV / sales1.89x
Earnings yield9.76%
Profitability
Operating margin (excl. other income)-15.63%
Operating margin (incl. other income)-14.75%
EBITDA margin18.72%
Pre-tax margin15.89%
Net profit margin15.88%
Net margin, latest quarter-7.80%
ROE-13.55%
ROCE-18.63%
ROA-6.31%
ROIC (approx.)10.35%
Tax rate19.20%
Other income / net worth0.91%
Growth
Sales growth (latest year)18.03%
Sales growth QoQ13.61%
Profit growth QoQ-217.76%
Sales growth YoY (latest quarter)-10.00%
Profit growth YoY (latest quarter)-118.68%
Per share
EPS (TTM)Rs 5.35
EPS (latest year)Rs -4.57
EPS (latest quarter)Rs -0.72
Book value per shareRs 35.42
Sales per shareRs 33.68
Cash flow per shareRs -15.16
Free cash flow per shareRs 2.43
Efficiency
Asset turnover0.47x
Fixed asset turnover0.83x
Inventory turnover2.75x
Inventory days132 days
Debtor days71 days
Debtors turnover5.16x
Creditor days80 days
Cash conversion cycle66 days
Working capital days34 days
Leverage
Total debtRs 25 Cr
Cash and bankRs 4 Cr
Net debtRs 21 Cr
Debt to equity0.29x
Net debt / EBITDA1.38x
Interest coverage18.86x
Owners' fund to total sources44.66%
Debt to assets12.89%
Cash flow
Cash from Operating Activity (latest year)Rs -37 Cr
Cash from Investing Activity (latest year)Rs -25 Cr
Cash from Financing Activity (latest year)Rs 64 Cr
Net Cash Flow (latest year)Rs 2 Cr
Free cash flow (latest year)Rs 6 Cr
FCFE (approx.: FCF + change in debt)Rs -0 Cr
Statement figures
Net sales (TTM)Rs 83 Cr
Net sales (latest year)Rs 91 Cr
Sales (latest quarter)Rs 23 Cr
Operating profit excl. other income (latest year)Rs -14 Cr
Operating profit (latest quarter)Rs -1 Cr
Other income (TTM)Rs 13 Cr
EBITDA (TTM)Rs 16 Cr
PBDT (TTM)Rs 15 Cr
Profit before tax (TTM)Rs 13 Cr
Tax (latest year)Rs -5 Cr
Net profit (TTM)Rs 13 Cr
Net profit (latest year)Rs -11 Cr
Net profit (latest quarter)Rs -2 Cr
Depreciation (TTM)Rs 2 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 76 Cr
Total expenditure (latest year)Rs 105 Cr
Total income (latest year)Rs 92 Cr
Share capitalRs 25 Cr
ReservesRs 63 Cr
Shareholders' fundsRs 87 Cr
Total assetsRs 196 Cr
Net blockRs 110 Cr
Capital work in progressRs 15 Cr
InvestmentsRs 0 Cr
ReceivablesRs 18 Cr
InventoryRs 28 Cr
Other liabilitiesRs 83 Cr
Shares outstanding (crore)2.47
Ownership
Promoter holding52.62% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | BROOKS | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -7.7% | -2.8% | -5.0 pts |
| 1 month | -17.6% | -6.8% | -10.8 pts |
| 3 months | -29.0% | -7.6% | -21.4 pts |
| 6 months | +47.7% | +0.4% | +47.3 pts |
| 1 year | -61.3% | -9.9% | -51.4 pts |
| 2 years | -62.1% | -13.6% | -48.5 pts |
| 3 years | -39.5% | +14.2% | -53.7 pts |
| 5 years | -58.5% | +27.9% | -86.3 pts |
1 mutual fund schemes hold about ₹20 Cr.
Over three months 0 bought more and 0 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| Quant Business Cycle Fund | 1.97% | 20 |
Red flags
F-score 3 of 8| explain | High accruals Profit exceeded operating cash by 13% of total assets in 2026 |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹23 Cr -10.0% vs Jun 2025.
Net loss ₹2 Cr.
Against our estimate for Jun 2026: sales +7.5%, profit -124.9% miss. Our estimate for Sep 2026: sales Rs 21 Cr, profit Rs 4 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2024-09-12 | Annual General Meeting | |
| 2023-09-14 | Annual General Meeting | |
| 2023-07-28 | Rights 1:16 @ Premium Rs 65/- | |
| 2022-09-22 | Annual General Meeting | |
| 2021-09-21 | Annual General Meeting | |
| 2020-09-18 | Annual General Meeting | |
| 2020-02-11 | Rights 9:20 @ Premium Rs 10/- | |
| 2019-09-17 | Annual General Meeting | |
| 2018-08-02 | Annual General Meeting | |
| 2017-09-20 | Annual General Meeting | |
| 2016-09-19 | Annual General Meeting | |
| 2015-09-21 | Annual General Meeting | |
| 2014-07-31 | Annual General Meeting | |
| 2013-08-29 | Annual General Meeting | |
| 2012-09-14 | Annual General Meeting |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
High low price variation greater than 150perc in previous 12 monthsHigh low price variation greater than 200perc in previous 365 Days
Quick answers
What is the market cap of Brooks Laboratories Ltd?
Brooks Laboratories Ltd (BROOKS) has a market capitalisation of Rs 166 Cr. at the 2026-10-01 close.
What is the P/E ratio of Brooks Laboratories Ltd?
Brooks Laboratories Ltd trades at a P/E of 12.6 on trailing twelve-month profit, at the 2026-10-01 close.
What were Brooks Laboratories Ltd's latest quarterly results?
In the Jun 2026 quarter, Brooks Laboratories Ltd sales was Rs 23 Cr (-10.0% vs Jun 2025) with a net loss of Rs 2 Cr.
What is the 52-week high and low of Brooks Laboratories Ltd?
The 52-week high is Rs 139.19 and the 52-week low is Rs 36.30.